Delivery
We have pioneered a new category of drug delivery of therapeutics for CNS-based diseases with the potential ability to shift the outcomes for patients around the globe.
Conjugated Delivery
In addition to NEO100’s potential ability to provide for transport to the Brain and potentially other areas where permeability is a factor in drug delivery. Our research suggests the formulation has a corollary advantage in that it can be conjugated with other therapeutics making a new conjugated drug.
By conjugating NEO100 with another therapeutic, such as Temozolomide (TMZ) in the case of NeOnc’s NEO212, the new drug potentially acquires a transport capability of NEO100 without losing any of the drug’s therapeutic efficacy. When it comes to creating new drug therapies for patients suffering from brain-based cancers such as glioblastoma multiforme, this conjugated approach potentially opens a whole new window of opportunity to provide more efficacious treatments.
With current IV and oral administration, the main hurdle to efficacy is first the dilution issue of having to have a therapeutic be transported systemically throughout a patient’s body and not just to where it needs to go, and secondly that when a drug does reach the brain, it is unable to effectively pass through the Blood-Brain Barrier (BBB) to enter the cerebral tissue (see the Blood-Brain Barrier section for more information).
As the images below show, large molecules, including most viruses or pathogens, and hydrophilic (water-based) molecules, such as the chemotherapeutic Temozolomide (TMZ), have difficulty passing through the tight junctions of the endothelial cells to enter the CSF or brain tissue. Our proprietary formulation of POH, as our research suggests, passes through because of its small molecular size and lipophilic (fat-soluble) structure.

The image above shows the large complex structure of a TMZ molecule and its difficulty in passing through the BBB.

The image above shows the small and lipophilic structure of a POH molecule and its potential ability to pass through the BBB.

The image above shows a POH conjugated formulation with TMZ and how this altered structure can potentially allow the combinatorial therapeutic to pass through the BBB.
When TMZ is conjugated with NeOnc’s proprietary POH formulation, our research suggests that the solvent nature of the POH alters the structure of TMZ enough to allow it to pass unaffected into the brain tissue.
This ability provides a leap forward in allowing pharma-based therapeutics to be delivered to the brain to effect a treatment while lowering some of the side effects associated with the high-dosing requirements currently used in traditional systemic delivery.